SVR after Treatment of HCV Genotype 1a with ABT-450/Ritonavir, Ombitasvir, and Dasabuvir is Enhanced by RBV in Noncirrhotic Patients and by Extension of Duration in Cirrhotic Patients

Brian Hoyle

doi:10.1177/155989771448015

Article Figures & Data

Figures

Tables

Download figure
Open in new tab
Download powerpoint
Figure 1.
SVR12 Rates in Cirrhotic HCV1a-Infected Treatment-Naïve and Treatment-Experienced Patients Treated for 12 or 24 Weeks
3D, 3-drug direct-acting antiviral regimen; HCV1a, hepatitis C virus genotype 1a; PegIFN, pegylated interferon; RBV, ribavirin; SVR12, sustained virologic response at week 12.

Tables

Figures

Download powerpoint

SVR after Treatment of HCV Genotype 1a with ABT-450/Ritonavir, Ombitasvir, and Dasabuvir is Enhanced by RBV in Noncirrhotic Patients and by Extension of Duration in Cirrhotic Patients

Citation Manager Formats

Thank you for your interest in spreading the word on MD Conference Express.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following SVR after Treatment of HCV Genotype 1a with ABT-450/Ritonavir, Ombitasvir, and Dasabuvir is Enhanced by RBV in Noncirrhotic Patients and by Extension of Duration in Cirrhotic Patients

Message Subject (Your Name) has sent you a message from MD Conference Express

Message Body (Your Name) thought you would like to see the MD Conference Express web site.

Your Personal Message

Main menu

Article Figures & Data

Figures

Tables

Tools

Cited By...

Keywords

Citation Manager Formats

Article Figures & Data

Figures

Tables

Tools

Table of contents

Cited By...

Keywords